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Background: Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer characterized by
the lack of estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2
(HER2) expressions. This subgroup of refractory disease tends to have aggressive clinical behavior, high frequency of
metastasis and lack of response to current hormonal or targeted therapies. Despite numerous studies reporting the
clinicopathological features of TNBC and its association with the basal-like phenotype in the Western population,
only limited data are available in the Asian population. Therefore, the aim of this study was to investigate the
clinicopathological characteristics of TNBC and its association with epidermal growth factor receptor (EGFR),
cytokeratin 5/6 (CK5/6) and mast/stem cell growth factor receptor (c-KIT or CD117) expression in Malaysian women.
Methods: A total of 340 patients diagnosed with primary breast cancer between 2002 and 2006 in Malaysia were
reviewed and analyzed.
Results: The incidence of TNBC was 12.4% (42/340). Bivariate analysis revealed that TNBC was strongly associated
with a younger age, higher grade tumor and p53 expression. Further immunohistochemical analysis suggested that
TNBC in Malaysian women was strongly associated with EGFR, CK5/6 and c-KIT expression with high a Ki-67
proliferation index.
Conclusion: In conclusion, our study confirms the association of TNBC with basal-like marker expression (EGFR,
CK5/6 and c-KIT) in Malaysian women, consistent with studies in other populations.
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The recent advances of DNA microarray technology has
enabled the classification of breast cancer into subgroups
based on the gene expression profile [1]. Based on the
study of these profiles, breast cancer can be divided into
five subtypes: luminal A, luminal B, basal-like, normal-like
and human epidermal growth factor receptor 2 (HER2)-
overexpressing subtype [1-3]. Of particular importance is
the basal-like subtype, which accounts for 15 to 20% of all
breast cancers and confers a markedly poor prognosis
compared to other subtypes [1,4,5].* Correspondence: cheeonn_leong@imu.edu.my
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distribution, and reproduction in any mediumThe majority of basal-like breast cancers exhibit a
“triple-negative” phenotype, characterized by the lack of
expression of the estrogen receptor (ER) or the proges-
terone receptor (PR) and a lack of HER2 amplification.
They also often have a high frequency of p53 mutations
[6,7].
In most cases, basal-like breast cancer is conveniently
defined based on the “triple-negative” phenotype. How-
ever, there is evidence that triple-negative breast cancers
(TNBC) and basal-like breast cancers (BLBC) might be
of two different biological entities [8-10]. Indeed, it has
been reported that only 80% of the tumor that express
basal-like markers (EGFR, CK5/6 and/or c-KIT) are
triple-negative in a Western population [1,4,8,11-13].
Although the clinicopathologic characteristics of the
basal-like carcinomas, compared with other subtypes,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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populations recently [14,15], the true relationship be-
tween triple-negative breast cancer and those showing
basal-like expression markers has not been enunciated.
Thus, our study aimed to investigate the pathology of
TNBC in Malaysian women and comprehend the rela-
tionship between TNBC and BLBC in our population.
Methods
Tissue and patient data
Patients diagnosed with primary breast cancer at the
Gleneagles Intan Medical Centre (GIMC), Malaysia, be-
tween 2002 and 2006 were included in the study. Clini-
copathological parameters including age, tumor size,
histological grade, histological subtype, associated ductal




AGE AT DIAGNOSIS (y)
≤ 40 15 (35.7%)
41≤ y≤ 49 13 (31.0%)
50≤ y≤ 65 13 (31.0%)






1 (well differentiated) 0 (0.0%)
2 (moderately differentiated) 6 (14.3%)
3 (poorly differentiated) 32 (76.2%)
Not determined 4 (9.5%)
TUMOR SIZE (cm)
≤ 2 12 (28.6%)
2 < cm≤ 5 15 (35.7%)
> 5 3 (7.1%)








Not determined 0 (0.0%)
Note: Percentage (%) indicates the percentage within the subgroup. DCIS ductal canodal status were evaluated. ER and PR statuses were
determined using a standard immunohistochemistry
(IHC) staining protocol on initial diagnostic material
using proteinase K antigen retrieval method followed by
mouse anti-human ERα monoclonal antibody (clone
1D5; DAKO, Denmark) and mouse anti-human PR
monoclonal antibody (clone PgR 636; DAKO, Denmark).
ER or PR positivity was defined as the presence of 1% or
more positively-stained tumor cells as described previ-
ously [16,17]. HER2 expression was determined using
the DAKO HerceptestW Kit (Dako, Carpinteria, CA,
USA) and scored according to international guidelines
[18]. HER2 scores of 0 and 1+ were considered negative.
HER2 scores of 2+ and 3+ were considered as HER2
overexpression [16]. All results were available from the
original pathology reports except for HER2 amplificationegative cases (TNBC) and non triple-negative cases (non-
No. of patients (%)
non-TNBC (N =298) TOTAL
49 (16.4%) 64 (18.8%)
113 (37.9%) 126 (37.1%)
107 (35.9%) 120 (35.3%)
29 (9.7%) 30 (8.8%)
35 (11.7%) 38 (11.2%)
232 (77.9%) 267 (78.5%)
31 (10.4%) 35 (10.3%)
7 (2.3%) 7 (2.1%)
110 (36.9%) 116 (34.1%)
151 (50.7%) 183 (53.8%)
30 (10.1%) 34 (10.0%)
109 (36.6%) 121 (35.6%)
99 (33.2%) 114 (33.5%)
15 (5.0%) 18 (5.3%)
75 (25.2%) 87 (25.6%)
91 (30.5%) 108 (31.8%)
194 (65.1%) 219 (64.4%)
13 (4.4%) 13 (3.8%)
45 (15.1%) 60 (17.6%)
251 (84.2%) 278 (81.8%)
2 (0.7%) 2 (0.6%)
rcinoma in-situ, IDC invasive ductal carcinoma.
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Triple-negative breast cancers (TNBC) were defined as
tumors that were ER, PR and HER2 negative. Non
triple-negative (non-TNBC) cases were defined as
tumors that express ER, PR or HER2. This study was
approved by the Institutional Review Board of the Inter-
national Medical University, Malaysia (IRB protocol
number IMU-BMS I02/2009-2). Written informed con-
sent for use of all human specimens in this study was
obtained at the time of enrollment.
Immunohistochemistry (IHC)
Immunohistochemistry (IHC) analysis of human epider-
mal growth factor receptor (EGFR), cytokeratin 5/6
(CK5/6), mast/stem cell growth factor receptor (c-KIT
or CD117) and Ki-67 was performed on formalin-fixed,
paraffin-embedded breast cancer tissue. Tissue blocksTable 2 Summary of clinical pathologic status of non triple-n
Characteristic
ER/PR+, HER2+ (N= 111)
AGE AT DIAGNOSIS (y)
≤ 40 21 (18.9%)
41≤ y≤ 49 42 (37.8%)
50≤ y≤ 65 37 (33.3%)






1 (well differentiated) 2 (1.8%)
2 (moderately differentiated) 50 (45.0%)
3 (poorly differentiated) 52 (46.8%)
Not determined 7 (6.3%)
TUMOR SIZE (cm)
≤ 2 46 (41.4%)
2 < cm≤ 5 32 (28.8%)
> 5 7 (6.3%)








Not determined 0 (0.0%)
Note: Percentage (%) indicates the percentage within the subgroup. DCIS ductal cawere sectioned at 4-μm thickness and deparaffinized in
xylene and rehydrated with graded ethanol. Heat-
induced epitope retrieval in Tris/EDTA pH 9.0 buffer
was used for CK5/6, c-KIT and Ki-67 staining, while
proteinase K enzymatic retrieval method was used for
EGFR staining. All primary antibodies were supplied by
Dako Corporation (Carpinteria, CA, USA). The dilution
factors were as follows: EGFR (clone E30), 1:50; CK5/6
(clone D5/16 B4), 1:50; cKIT polyclonal, 1:400; and Ki-67
(clone MIB-1), 1:100. EGFR, CK5/6 or c-KIT positivity
was defined as the presence of 1% or more positively-
stained tumor cells as described previously [8,19].
Determination of proliferation indices
To estimate the growth rate of tumors, the percentage
of tumor cells expressing the proliferation marker Ki-67
was measured. A proliferation index was calculated foregative cases (non-TNBC)
No. of patients (%)
ER/PR+, HER2- (N =106) ER/PR-, HER2+ (N =81)
17 (16.0%) 11 (13.6%)
45 (42.5%) 26 (32.1%)
33 (31.1%) 37 (45.7%)
11 (10.4%) 7 (8.6%)
13 (12.3%) 8 (9.9%)
74 (69.8%) 69 (85.2%)
19 (17.9%) 4 (4.9%)
4 (3.8%) 1 (1.2%)
48 (45.3%) 12 (14.8%)
35 (33.0%) 64 (79.0%)
19 (17.9%) 4 (4.9%)
44 (41.5%) 19 (23.5%)
27 (25.5%) 40 (49.4%)
2 (1.9%) 6 (7.4%)
33 (31.1%) 16 (19.8%)
24 (22.6%) 33 (40.7%)
74 (69.8%) 45 (55.6%)
8 (7.5%) 3 (3.7%)
7 (6.6%) 28 (34.6%)
97 (91.5%) 53 (65.4%)
2 (1.9%) 0 (0.0%)
rcinoma in-situ, IDC invasive ductal carcinoma.
Table 3 Summary of the clinical pathological status of
TNBC and non-TNBC used for EGFR, CK5/6 and c-KIT
immunohistochemical analysis
Characteristic No. of patients (%)
TNBC (N=18) non-TNBC (N=18)
AGE AT DIAGNOSIS (y)
≤ 40 3 (16.6%) 2 (11.1%)
41≤ y≤ 49 10 (55.5%) 7 (38.9%)
50≤ y≤ 65 5 (27.7%) 6 (33.3%)
> 65 0 (0.0%) 3 (16.7%)
GRADE
1 (well differentiated) 0 (0%) 0 (0%)
2 (moderately differentiated) 3 (16.6%) 5 (27.8%)
3 (poorly differentiated) 15 (83.3%) 13 (72.2%)
TUMOR SIZE (cm)
≤ 2 7 (38.9%) 5 (27.8%)
2 < cm≤ 5 5 (27.8%) 9 (50.0%)
> 5 3 (16.7%) 1 (5.6%)
Unknown 3 (16.7%) 3 (16.7%)
LYMPH NODE INFILTRATION
Positive 4 (21.1%) 8 (44.4%)
Negative 14 (77.8%) 10 (55.6%)
Note: Percentage (%) indicates the percentage within the subgroup.
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tumor cell nuclear profiles and the number of
Ki-67-positive nuclear profiles in randomly and system-
atically selected fields as described previously [20-22]. On
average, 500 nuclear profiles were counted per tumor
lesion.
Statistical analysis
The Fisher’s exact test was used to analyze the correlation
between the triple-negative phenotype and EGFR, CK5/6
or c-KIT expression. The Student’s t-test and Mann–Whit-
ney test was used to compare the Ki-67 proliferaton index
of TNBC and non-TNBC. All statistical analyses were per-
formed using SPSS for Windows (Version 11). A P value of
less than 0.05 was considered statistically significant.
Results
Triple-negative breast cancer is associated with a younger
age and high tumor grade in Malaysian women
A total of 340 breast cancer patient records obtained
from the Gleneagles Hospital, Malaysia, from 2002 to
2006 were reviewed and analyzed. The majority of
patients were middle aged between 41 and 65 years old,
and had a mean age of 49.4 ± 10.4 years. The median age
was 48 years. Most of the cases were invasive ductal car-
cinoma (IDC), accounting for 78.5% of all cases. The
majority of these patients also presented with a grade 2
or 3 tumor. The tumor size had a mean of 2.6 ± 1.4 cm
and a median of 2.2 cm. Lymph node infiltration and
p53 expression were not common in this cohort of
patients. The clinical pathological status of the investi-
gated cohort is summarized in Table 1.
All cases were further stratified based on ER, PR and
HER2 statuses. A total of 42 cases (12.4%) were identi-
fied to be TNBC and the remaining 298 cases (87.6%)
expressed at least one of the markers and were classified
as non-TNBC cases. Among all the non-TNBC cases, a
total of 111 (37.2%) cases were ER/PR+ and HER2+, 106
(35.6%) cases were ER/PR + and HER2-, and 81 (27.2%)
cases were ER/PR- and HER2+ (Table 2). Of note, the
majority of patients diagnosed with TNBC were of a
younger age (below 40 years) with a mean age of
45.3 ± 10.3 years versus 50.0 ± 10.4 years in the non-
TNBC cases (Student’s t-test, P= 0.0029). In addition,
most of the TNBC cases were high grade tumors with
76.2% of the cases diagnosed as grade 3 versus 50.7% in
the non-TNBC group.
Although the tumor size from the TNBC cases were
slightly larger (2.8 ± 1.6 cm) compared to non-TNBC
cases (2.5 ± 1.4 cm), the difference, however, was not sta-
tistically significant (Student’s t-test, P= 0.153). Similarly,
no differences in histology (IDC vs DCIS) (Fisher’s exact
test, P= 0.322) and lymph node infiltration rate (Fisher’s
exact test, P= 0.177) were observed between TNBC andnon-TNBC cases. Thus, the major differences between
TNBC and non-TNBC were age and tumor grade, in
which TNBC patients were younger and with high grade
tumors compared to non-TNBC patients.Triple-negative breast cancer is strongly associated with
EGFR, CK5/6 and/or c-KIT expression
Based on the available clinical data, tissue samples from
a total of 36 patients were reviewed and retrieved for
EGFR, CK5/6 and c-KIT staining. Of the 36 samples, 18
were TNBC and 18 were non-TNBC based on the prior
ER, PR and HER2 staining. All cases were age and grade
matched as closely as possible and the majority was
grade 3 tumors. The clinical pathological features of the
cases included in the current study are summarized in
Table 3.
Of all the TNBC cases, 61% (11/18) were EGFR+, 72%
(13/18) were CK5/6+ and 89% (16/18) were c-KIT+. In
stark contrast, only 11% (2/18) were EGFR+, 6% (1/18)
were CK5/6+ and 28% (5/18) were c-KIT + in the non-
TNBC group (Figure 1 and Table 1). Furthermore, 56%
(10/18) of the TNBC cases were both EGFR + and CK5/6+,
while none of the non-TNBC cases exhibited co-expression
of these markers. Thus, EGFR, CK5/6 or c-KIT expression
is strongly associated with TNBC in Malaysian women
(Fisher’s exact test, P< 0.01) (Table 4).


















Figure 1 EGFR, CK5/6 and c-KIT expression is associated with TNBC. (A) A total of 18 TNBC and 18 non-TNBC were stained for EGFR, CK5/6
and c-KIT by IHC. (B) Representative immunostaining results for tumors that are EGFR, CK5/6 and c-KIT positive or negative.
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To further characterize the phenotypes of breast cancers
in Malaysian women, we also analyzed the Ki-67 prolif-
eration index in TNBC and non-TNBC cases in the
current cohort. Thirty six out of 38 specimens (16 TNBC
and 18 non-TNBC cases) were stained with a
Ki-67-specific antibody (clone MIB-1) and the prolifera-
tion index was estimated as the percentage of Ki-67-
positive nuclear profiles in randomly and systematically
selected fields. As shown in Figure 2, TNBC had a signifi-
cantly higher Ki-67 index than non-TNBC tumors in
Malaysian women (Student’s t-test, P= 0.003 and Mann-
Whitey test, P < 0.004). The mean proliferation index for
TNBC and non-TNBC tumors were 47.48 ± 17.55 and31.43 ± 11.81, respectively. The median proliferation
index was 45.98 and 32.39 for TNBC and non-TNBC, re-
spectively. These results suggest that TNBC has a higher
proliferation rate than non-TNBC in Malaysian women.
Discussion
Breast cancer is a heterogeneous group of disease that
can be characterized into clinically, morphologically and
biologically distinct subgroups [14,23]. By gene expres-
sion profiling and IHC markers, breast cancers can be
classified into five major subtypes: luminal A (ER + and/
or PR+, HER2-), luminal B (ER + and/or PR+, HER2+),
HER2-overexpressing (ER-, PR-, HER2+), basal-like (ER-,
PR-, HER2-, CK5/6+ and/or EGFR+) and normal breast-
Table 4 Association of TNBC with EGFR, CK5/6 and/or c-KIT expression
IHC Staining TNBC (%) Non-TNBC (%) Fisher’s exact test (P value)
EGFR
Positive 11 (61.1%) 2 (11.1%) 4.5 x 10-5
Negative 7 (38.9%) 16 (88.9%)
CK 5/6
Positive 13 (72.2%) 1 (5.6%) 8.3 x10-3
Negative 5 (27.8%) 17 (94.4%)
c-KIT
Positive 16 (88.9%) 5 (27.8%) 4.9 x10-5
Negative 2 (11.1%) 13 (72.2%)
EGFR and/or CK 5/6
Positive 14 (77.8%) 3 (16.7%) 6.1 x10-4
Negative 4 (22.2%) 15 (83.3%)
EGFR and/or CK 5/6 or c-KIT
Positive 17 (94.4%) 6 (33.3%) 3.0 x10-4
Negative 1 (5.6%) 12 (66.7%)
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the basal-like subtype, which accounts for 15 to 20% of
all breast cancers and confers a markedly poor prognosis
[1,4,5]. Recent studies have shown that basal-like breast
cancers are likely to be mitotically active high-grade in-
vasive tumors that are associated with a younger patient
age [4,26,27]. A population-based study also identified
this subtype to be more prevalent in premenopausal


























Figure 2 TNBC has a higher growth rate. (A) Ki-67 proliferation index w
TNBC). •, Ki-67 proliferation index of each tumor; —, the median Ki-67 proli
nuclear profiles were counted per tumor lesion. (B) Representative immunoBRCA-1 mutation [4,12,26,27]. Due to their lack of ER,
PR and HER2 expression, basal-like breast cancers are
also unlikely to respond to anti-estrogen hormonal ther-
apies or trastuzumab [26,28].
To date, the gold standard for identifying basal-like
breast cancers is based on gene expression profiling. How-
ever, cost and technical issues have rendered gene expres-
sion profiling impractical as a routine diagnostic tool in
the clinical setting. In the Western population,High Ki-67
Low Ki-67
as used to estimate the growth rate of tumors (16 TNBC and 18 non-
feration index in the TNBC and non-TNBC subgroup. On average, 500
staining of tumors that have a high or low Ki-67 proliferation index.
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cers (ER-, PR-, HER2-) express basal markers, resulting in
the triple-negative subtype commonly used as a surrogate
marker for the basal-like subtype [1,4,8,18,29-37]. Rela-
tively little is known about this disease entity within Asian
populations, and in particular Malaysian populations.
Within the small cohort of 340 breast cancer patients
described in this study, a total of 42 cases (12.4%) were
identified as triple-negative. This proportion was slightly
lower than the recent studies in the Malaysian, Japanese,
Chinese and Korean populations that estimated the
prevalence of TNBC to be around 15 to 20% [23,38-41].
Consistent with earlier studies, our results showed that
TNBC in Malaysian women was strongly associated with
a younger age and high grade tumors compared to non-
TNBC [5,10,14,15,38,42]. However, no significant differ-
ences in tumor size, histology (IDC vs DCIS) and lymph
node infiltration rates were observed between TNBC
and non-TNBC in the current study.
Further analysis was carried out to investigate the ex-
pression of EGFR, CK5/6 and c-KIT in TNBC and non-
TNBC specimens. Due to the lack of information on
HER2 amplification, only tumors with HER2 scores of 0
were included in the TNBC cohort. Our results demon-
strated that TNBC in Malaysian women was strongly
associated with EGFR, CK5/6 and c-KIT expression.
Our results also showed that TNBC had a significantly
higher Ki-67 proliferation index than non-TNBC, sug-
gesting that TNBC could be more progressive.
Numerous studies have also shown that basal-like
breast cancer can be specifically identified using IHC
surrogate panels including ER, PR and HER2 negativity
and either EGFR or CK5/6 positivity (ER-, PR-, HER2-,
CK5/6+ and/or EGFR+) [8,19,26,43,44]. Using such sur-
rogates, our study showed that 78% (14/18) of TNBC
can be categorized as basal-like breast cancers. This pro-
portion is consistent with previous studies that also
show that 71.5% of TNBC are basal-like by gene expres-
sion profiling [30].Conclusions
In conclusion, the incidence of TNBC in this small co-
hort, predominantly Asian population, is comparable to
reported data in other populations. Consistent with
other studies, TNBC in Malaysian women is associated
with a younger age and higher grade of tumor, as well as
p53 expression in bivariate analysis. Our findings also
confirm that TNBC in Malaysian women strongly corre-
lates with EGFR, CK5/6 and c-KIT expression, and have
a higher proliferation rate.Competing interests
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